Science
Outpoll Weekly Recap: Science (May 4 – 10, 2026)
KE
Kevin White
11 hours ago7 min read
This week in science felt like flipping through the lab notebook of the future—CRISPR took another step toward rewriting our genetic code, and the markets caught the scent. Prediction platforms saw a surge in contracts tied to the first FDA-approved in vivo gene-editing therapy, currently trading at 72% probability for a 2027 approval, reflecting a quiet confidence in the field’s trajectory after Vertex and CRISPR Therapeutics quietly released Phase II data showing durable hemoglobin correction in 89% of beta-thalassemia patients.On the climate front, NOAA’s updated aerosol injection models lit up prediction markets for geoengineering deployment, with the “first major SRM field test before 2030” contract jumping to 34%—double what it was just six months ago—fueled by a controversial white paper out of Harvard’s Solar Geoengineering Research Program that argued for a “graduated, transparent escalation” of stratospheric experiments. Meanwhile, the AI-biology crossover deepened: a team at the Broad Institute open-sourced a protein-folding model that outperforms AlphaFold3 on disordered regions (those annoying floppy bits that make drug design a nightmare), and prediction markets now assign a 41% chance that a Nobel Prize in Chemistry will go to an ML-driven discovery within three years.The mRNA platform wars are heating up too—Moderna’s next-gen flu shot, mRNA-1020, cleared a Phase III endpoint with 68% efficacy against drifted H3N2 strains, pushing the “universal flu vaccine before 2032” contract to 58%. It’s a week where the boundary between science fiction and clinical reality continued to blur, and the markets—ever the cold-blooded forecasters—are starting to price in the next decade like it’s already happening.If you blinked, you might have missed the moment when we stopped asking “if” and started betting on “when. ”.
#Weekly recap
Stay Informed. Act Smarter.
Get weekly highlights, major headlines, and expert insights — then put your knowledge to work in our live prediction markets.
Related News
Comments
It's quiet here...Start the conversation by leaving the first comment.